Pharmamarketeer

EMA committee recommends approval of Bristol─Myers Squibb’s new Opdivo dosing regimen

Bristol─Myers Squibb Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) flat dosing schedule of 240 mg infused over 30 minutes every two weeks

Medhc-fases-banner
Advertentie(s)